Boehringer Ingelheim to present new atrial fibrillation data at ESC Congress

Boehringer Ingelheim has announced plans to share new clinical data on atrial fibrillation therapies at this year's European Society of Cardiology (ESC) Congress.

The company will attend the conference in Barcelona from August 26th to 30th to share data that will inform physicians on different aspects of treatment for patients with atrial fibrillation, with a total of four abstracts having been accepted.

Results from the RE-DUAL PCI trial have been selected for inclusion in one of the late-breaking science sessions of the congress, with the findings of this trial offering evidence of the safety and efficacy of the anticoagulant Pradaxa.

The trial compared treatment with either Pradaxa and a single antiplatelet agent or warfarin and two antiplatelets among approximately 2,500 adults with atrial fibrillation after percutaneous coronary intervention with stent placement.

Doses investigated in this trial have already demonstrated effective stroke prevention in atrial fibrillation and are therefore approved around the world in this indication.

Professor Jorg Kreuzer, vice-president for cardiovascular medicine at Boehringer Ingelheim, said: "We are honoured that the results will be included in the congress spotlight session and hope that the findings from the trial will provide a valuable contribution to patient management in the PCI setting."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.